Predictmedix Inc.

As of January 31, 2023, Predictmedix Inc. has 122.05M shares outstanding.

These figures are as of January 31, 2023. The price-to-sales ratio is 222.93, and the price-to-book ratio stands at -4.27.

These figures are as of January 31, 2023. The EV/Sales ratio of 221.75 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative.

As of January 31, 2023, Predictmedix Inc. maintains a current ratio of 0.16, meaning it holds 0.2x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended January 31, 2023. Return on assets (ROA) is negative at -211.60, reflecting losses generated across the asset base.

Over the twelve months ended January 31, 2023, Predictmedix Inc. posted a gross margin of 76.01, reflecting its pricing power and cost economics. The operating margin of -5,896.31 and net profit margin of -5,904.50 provide insight into operational efficiency.

These figures cover the twelve months ended January 31, 2023. Free cash flow yield is negative at -4.99: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -7.00, meaning Predictmedix Inc. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

As of January 31, 2023, Predictmedix Inc. has an Altman Z-Score of -64.38, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.